scholarly journals A Prospective Randomized, Double-Blind, Two-Period Crossover Pharmacokinetic Trial Comparing Green Coffee Bean Extract-A Botanically Sourced Caffeine-With a Synthetic USP Control

2018 ◽  
Vol 7 (8) ◽  
pp. 871-879
Author(s):  
Kayce Morton ◽  
Katelin Knight ◽  
Douglas Kalman ◽  
Susan Hewlings
Keyword(s):  
Coffee Bean ◽  
Green Coffee ◽  
Double Blind ◽  
Green Coffee Bean Extract ◽  
Green Coffee Bean

scholarly journals Supplementation of green coffee bean extract in healthy overweight subjects increases lean mass/fat mass ratio: A randomized, double-blind clinical study

2021 ◽  
Vol 9 ◽  
pp. 205031212110025
Author(s):  
HV Sudeep ◽  
K Shyam Prasad
Keyword(s):  
Body Mass Index ◽  
Body Weight ◽  
Body Mass ◽  
Vital Signs ◽  
Coffee Bean ◽  
Green Coffee ◽  
Double Blind ◽  
Green Coffee Bean Extract ◽  
Green Coffee Bean ◽  
Overweight Subjects

Objective: In this study, we have demonstrated that supplementation of a complex of chlorogenic acid isomers (CGA-7TM) could significantly mitigate the risk of obesity in healthy overweight subjects. Method: In a double-blind, placebo-controlled clinical study, healthy overweight (body mass index ⩾ 25 to <30 kg/m2) male and female subjects ( N = 71) were randomly allocated to receive 500 mg CGA-7 or placebo daily for 12 weeks. Changes in body weight and body mass index were recorded alongside vital signs and anthropometric measurements at week 4, 8 and 12. Body composition was assessed at baseline and the end of treatment using dual-energy X-ray absorptiometry. Safety analysis included serum biochemical and haematological assessments and measurement of vital signs. In addition, any adverse or serious adverse events were recorded during the study. Results: Sixty subjects completed the study. Mean body weight and body mass index were significantly reduced in CGA-7 group as compared to placebo ( p < 0.001). CGA-7 group showed significant changes in body fat (%), fat mass and lean mass in comparison with placebo group (1.38% ± 1.4% vs −0.22% ± 0.86%, 1.97 ± 1.44 kg vs −0.39 ± 1.31 kg; 0.81 ± 1.20 kg vs −0.13 ± 0.97 kg, p < 0.001). Consumption of CGA-7 significantly improved the serum lipid profile. Importantly, CGA-7 consumption in humans had no adverse effects and was well tolerated during the study. The blood biochemical and haematological parameters marginally varied in the treatment groups throughout the study. Conclusion: To conclude, this study provides scientific validation of the functionality of green coffee bean extract and recommends the safety of the supplementation in healthy individuals.

scholarly journals Acute and sub-chronic toxicity evaluation of a standardized green coffee bean extract (CGA-7™) in Wistar albino rats

2021 ◽  
Vol 9 ◽  
pp. 205031212098488
Author(s):  
Venkatakrishna K ◽  
Sudeep HV ◽  
Shyamprasad K
Keyword(s):  
Oral Dose ◽  
Chronic Toxicity ◽  
Clinical Signs ◽  
Albino Rats ◽  
Coffee Bean ◽  
Green Coffee ◽  
Toxicological Assessment ◽  
Limit Test ◽  
Green Coffee Bean Extract ◽  
Green Coffee Bean

Objective: Despite having numerous physiological benefits, toxicological assessment of green coffee beans is sparce. Here, we document the oral acute and sub-chronic toxicity of a standardized decaffeinated green coffee bean extract containing 50% chlorogenic acids (CGA-7™) in rats. Methods: We have performed a limit test at single oral dose of 2000 mg/kg to evaluate the acute toxicity in female Wistar rats. Furthermore, repeated dose 90-day toxicity study was conducted to assess the risk of long-term use of CGA-7. Result: A 14-day observation revealed no clinical signs of toxicity or mortality in animals at 2000 mg/kg acute oral dose of CGA-7. The administration of 250, 500, and 1000 mg/kg CGA-7 showed significant alterations in some parameters such as food consumption, relative organ weights of brain and spleen, haematological and biochemical parameters compared to control. These changes were not consistent and dose-dependent throughout the study. Furthermore, the changes were within the physiological range and toxicologically insignificant. CGA-7 did not affect the normal metabolism and physiology of the animals up to 1000 mg/kg dose. Macroscopic and histological examination of organs did not reveal any organ toxicity. Conclusion: Finally, the findings from this study suggest the safety of green coffee bean extract.

scholarly journals Decaffeinated Green Coffee Bean Extract Attenuates Diet-Induced Obesity and Insulin Resistance in Mice

2014 ◽  
Vol 2014 ◽  
pp. 1-14 ◽  
Author(s):  
Su Jin Song ◽  
Sena Choi ◽  
Taesun Park
Keyword(s):  
Insulin Resistance ◽  
Adipose Tissue ◽  
Plasma Lipids ◽  
Body Weight Gain ◽  
Chow Diet ◽  
Coffee Bean ◽  
Green Coffee ◽  
Visceral Adipose ◽  
Green Coffee Bean Extract ◽  
Green Coffee Bean

This study investigated whether decaffeinated green coffee bean extract prevents obesity and improves insulin resistance and elucidated its mechanism of action. Male C57BL/6N mice(N=48)were divided into six dietary groups: chow diet, HFD, HFD-supplemented with 0.1%, 0.3%, and 0.9% decaffeinated green coffee bean extract, and 0.15% 5-caffeoylquinic acid. Based on the reduction in HFD-induced body weight gain and increments in plasma lipids, glucose, and insulin levels, the minimum effective dose of green coffee bean extract appears to be 0.3%. Green coffee bean extract resulted in downregulation of genes involved in WNT10b- and galanin-mediated adipogenesis and TLR4-mediated proinflammatory pathway and stimulation of GLUT4 translocation to the plasma membrane in white adipose tissue. Taken together, decaffeinated green coffee bean extract appeared to reverse HFD-induced fat accumulation and insulin resistance by downregulating the genes involved in adipogenesis and inflammation in visceral adipose tissue.

Sign in / Sign up

Export Citation Format

Share Document